Volume 20, Issue 4

Dear Friends, It was very nice to see so many familiar faces at the recent UEGW meeting in Berlin, and even better to see so many Y-ECCO Members making important contributions. The days are getting shorter and colder, which can mean only one thing… the ECCO Congress is coming!

The IL-22–oncostatin M axis promotes intestinal inflammation and tumorigenesis Cineus R, Luo Y, Saliutina M, et al. Nature Immunology 2025;26:837–53. doi: 10.1038/s41590-025-02149-z.

Physiological data collected from wearable devices identify and predict inflammatory bowel disease flares – The IBD Forecast Study Hirten RP, Danieletto M, Sanchez-Mayor M, et al. Gastroenterology 2025;168:939–51.e5. doi: 10.1053/j.gastro.2024.12.024.

Early infliximab levels and clearance predict outcomes after infliximab rescue in acute severe ulcerative colitis: Results from PREDICT-UC Li Wai Suen CFD, Choy MC, Con D, et al. Gastroenterology 2025 July 21. doi: 10.1053/j.gastro.2025.07.020

Robin Dart is widely recognised within the IBD Community—not only as a dedicated clinician-scientist but also as a leading voice for early-career professionals through his role in Y-ECCO since 2022. As current Chair of the Y-ECCO Committee, he has helped shape the future of the next generation in ECCO. In this edition of the Y-ECCO Interview Corner, we speak with Robin about his personal journey, his vision for an inclusive and collaborative Y-ECCO, and the lessons he has learned along the way.

Dear ECCO Friends and Community, In this new episode of ECCO News – Meet the Reps I had the pleasure of speaking with Prof. Juozas Kupčinskas, IBD National Representative for Lithuania, about his role within ECCO and his perspectives on advancing IBD care and research at both national and European levels.